Showing results (61-70 of 83) with videos related to
Sort By:
Pageof 9
Diabetes & Metabolism Journal|January 5, 2025
Study Design and Protocol for a Randomized Controlled Trial of Enavogliflozin to Evaluate Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP)Nam Hoon Kim, Soo Lim, In-Kyung Jeong, et al.Diabetes & Metabolism Journal|May 23, 2014
Prevalence and determinants of diabetic nephropathy in Korea: Korea national health and nutrition examination surveyJae Hee Ahn, Ji Hee Yu, Seung-Hyun Ko, et al.Journal of Korean Medical Science|December 18, 2010
Type 2 diabetes in urban and rural districts in Korea: factors associated with prevalence differenceHye Young Lee, Jong Chul Won, Yoon Jung Kang, et al.Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 19, 2022
The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trialTae-Hyun Yoo, Soon Jun Hong, Sunggyun Kim, et al.Diabetes, Obesity & Metabolism|February 26, 2026
Effectiveness and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus: A Multicenter, Prospective, Observational StudyJun Hwa Hong, Sung Hoon Yu, Ki-Hyun Baek, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|December 8, 2009
Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha overexpression prevents endothelial apoptosis by increasing ATP/ADP translocase activityJong Chul Won, Joong-Yeol Park, Yun Mi Kim, et al.Diabetes & Metabolism Journal|November 8, 2013
Prevalence of Diabetes and Prediabetes according to Fasting Plasma Glucose and HbA1cJa Young Jeon, Seung-Hyun Ko, Hyuk-Sang Kwon, et al.Diabetes, Obesity & Metabolism|March 5, 2023
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trialSoo Heon Kwak, Kyung Ah Han, Kyung-Soo Kim, et al.Diabetes, Obesity & Metabolism|March 1, 2024
A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozinSoo Lim, Seung-Hwan Lee, Kyung-Wan Min, et al.Diabetes, Obesity & Metabolism|July 26, 2024
Long-term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52-week extension of a Phase 3 randomized controlled trialSoo Heon Kwak, Kyung Ah Han, Eun Sook Kim, et al.Pageof 9